Mgi Pharma Inc

Mgi Pharma — UBS Global Life Sciences Conference 2004

9 slides from Mgi Pharma's conference presentation, Sep 27, 2004

  1. Slide 1: MGI PHARMA, INC. Presented at the UBS Global Life Sciences Conference

    MGI PHARMA, Presented September at27, the2004 UBS INC.Global Life Sciences Conference

  2. Slide 2: Forward-Looking Statements

    Forward-Looking This presentation contains Statements forward-looking statements that involve risks and uncertainties, including those described in the Company’s Securities and Exchange Commission filings.

  3. Slide 3: MGI PHARMA Product Portfolio

    MGI PHARMA Product Preclinical Kadian® Aloxi® Irofulven Combination Injection portfolio Capsules Monotherapy Phase Therapy (CINV) (PONV) 1 (oncology Phase MG98 2Salagen® Aloxi® Phase Other pain)3oral Dacogen™ Acylfulvene FDA Tablets formulation Review Hexalen® (MDS) Analogs Market Capsules Saforis™

  4. Slide 4: Morphine Kadian® Oncology Franchise

    Morphine Kadian® 3 Oncology franchise year promotion sulfate by launch sustained agreement MGI PHARMA release from Alpharma capsules in September for oncology 2004 Promotion pain Indicated revenue for management will be used to ofhelp moderate offset to R&D severe associated pain where withtreatment

  5. Slide 5: Anti-cancer Dacogen™

    Anti-cancer Dacogen™ WW $40M $15M 20% Phase NDA MGI to licensing PHARMA’s and 3committed equity 30% trial MAA agent in royalty investment, agreement MDS submissions development core with tocomplete capabilities SuperGen broad $45M withexpected clinical SuperGen funding in milestones of activity onco

  6. Slide 6: Saforis™ Phase 3 Oral Mucositis

    Phase Saforis™ To $32M 5% Proprietary One Primary Significant Second Builds be royalty phase obtained 3in on phase candidate endpoint cash MGI 3activity on formulation trial plus 3sales through PHARMA’s trial complete met for milestone into expected oral prevention (p=0.026): Aesgen acquisition of m

  7. Slide 7: Immunotherapeutic ZYC101a

    Immunotherapeutic ZYC101a Obtained $50M Immune In Overall, Phase a prospectively 3cash pivotal 43% response through transaction resolution program acquisition therapeutic defined for cervical for expected population ZYC101a of fordysplasia Zycos treatment to begin of patients patients early of cervi

  8. Slide 8: Updated Financial Guidance FY 2004

    FY R&D Updated Aloxi Cost process Q3 Loss 2004 of before injection product research September Financial is expected interest sales sales and Guidance & 27, of development to astaxes $140 be 2004 a percent approximately ofto$85 $150 of and million sales million nonrecurring $7.5M, revenue Other exclu

  9. Slide 9: Financial Guidance FY 2005

    FY provided As Total Product 2005 revenues candidates Financial September of approx. Guidance acquired 1,$280 2004 andmillion announced Totalon operating September expenses 1, 2004 ofcould $205 add million $500EBIT million of $75 in combined million net sales to revenue 3 to 4 years after launch

MGI Pharma — UBS Global Life Sciences Conference 2004 on 6ix